Clinical outcome assessment in malignant glioma trials: Measuring signs, symptoms, and functional limitations

Jaishri Blakeley, Stephen Joel Coons, John R. Corboy, Nancy Kline Leidy, Tito R. Mendoza, Jeffrey S. Wefel

Research output: Contribution to journalArticle

Abstract

The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.

Original languageEnglish (US)
Pages (from-to)ii13-ii20
JournalNeuro-Oncology
Volume18
DOIs
StatePublished - Mar 1 2016

Fingerprint

Glioma
Signs and Symptoms
Outcome Assessment (Health Care)
Psychometrics
Brain Neoplasms
Clinical Trials
Survival
Population
Neoplasms
Patient Reported Outcome Measures
Therapeutics

Keywords

  • clinical outcome assessment
  • clinical trials
  • endpoints
  • malignant glioma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology

Cite this

Clinical outcome assessment in malignant glioma trials : Measuring signs, symptoms, and functional limitations. / Blakeley, Jaishri; Coons, Stephen Joel; Corboy, John R.; Leidy, Nancy Kline; Mendoza, Tito R.; Wefel, Jeffrey S.

In: Neuro-Oncology, Vol. 18, 01.03.2016, p. ii13-ii20.

Research output: Contribution to journalArticle

Blakeley, Jaishri ; Coons, Stephen Joel ; Corboy, John R. ; Leidy, Nancy Kline ; Mendoza, Tito R. ; Wefel, Jeffrey S. / Clinical outcome assessment in malignant glioma trials : Measuring signs, symptoms, and functional limitations. In: Neuro-Oncology. 2016 ; Vol. 18. pp. ii13-ii20.
@article{7825a3c6fba84b0c88e7048c11c76c76,
title = "Clinical outcome assessment in malignant glioma trials: Measuring signs, symptoms, and functional limitations",
abstract = "The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.",
keywords = "clinical outcome assessment, clinical trials, endpoints, malignant glioma",
author = "Jaishri Blakeley and Coons, {Stephen Joel} and Corboy, {John R.} and Leidy, {Nancy Kline} and Mendoza, {Tito R.} and Wefel, {Jeffrey S.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1093/neuonc/nov291",
language = "English (US)",
volume = "18",
pages = "ii13--ii20",
journal = "Neuro-Oncology",
issn = "1522-8517",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Clinical outcome assessment in malignant glioma trials

T2 - Measuring signs, symptoms, and functional limitations

AU - Blakeley, Jaishri

AU - Coons, Stephen Joel

AU - Corboy, John R.

AU - Leidy, Nancy Kline

AU - Mendoza, Tito R.

AU - Wefel, Jeffrey S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.

AB - The shared goal of all parties developing therapeutics against malignant gliomas is to positively impact the lives of people affected by these cancers. Clinical outcome assessment (COA) tools, including measures of patient-reported outcome, performance outcome, clinician-reported outcome, and observer-reported outcome, allow patient-focused assessments to complement traditional efficacy measures such as overall survival and radiographic endpoints. This review examines the properties of various COA measures used in malignant glioma clinical trials to date and cross references their content to the priority signs, symptoms, and functional limitations defined through a community survey conducted by the National Brain Tumor Society. The overarching goal of this initiative is to identify COA measures that are feasible and have appropriate psychometric properties for use in this patient population as well as highlight where further development is needed.

KW - clinical outcome assessment

KW - clinical trials

KW - endpoints

KW - malignant glioma

UR - http://www.scopus.com/inward/record.url?scp=84965170153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965170153&partnerID=8YFLogxK

U2 - 10.1093/neuonc/nov291

DO - 10.1093/neuonc/nov291

M3 - Article

C2 - 26989128

AN - SCOPUS:84965170153

VL - 18

SP - ii13-ii20

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

ER -